CASP1 and psoriasis: VX765 is a specific caspase-1 inhibitor that has been approved by the FDA to be used in clinical trials of adult patients with psoriasis (ClinicalTrials.gov Identifier: NCT00205465) and epilepsy (ClinicalTrials.gov Identifier: NCT01048255 and NCT01501383).